Dentsply Sirona Inc is a global leader in the dental industry, specializing in the manufacturing and distribution of a wide range of dental products and technologies. The company provides innovative solutions for dental professionals, including equipment, instruments, and materials used in various dental procedures, such as restorative, preventive, and orthodontic care. Dentsply Sirona focuses on improving patient outcomes through advancements in dental technology, offering products that enhance treatment efficiency and effectiveness. By catering to dental professionals worldwide, the company plays a pivotal role in enhancing oral health and clinical practice standards. Read More
Shares of dental products company Dentsply Sirona (NASDAQ:XRAY)
fell 13.4% in the morning session after it reported disappointing third-quarter results, highlighted by a significant earnings miss and a lowered forecast for the full year. While revenue of $904 million declined 4.9% year-over-year, it narrowly beat analysts' expectations. The main concern for investors was profitability, as adjusted earnings per share came in at $0.37, missing Wall Street's consensus estimate of $0.45 and falling sharply from $0.50 in the same quarter last year. The company's operating margin was negative 24.1%, underscoring its struggles with costs. Compounding the negative news, management lowered its full-year adjusted EPS guidance to a midpoint of $1.60. The combination of missing current earnings estimates and reducing future expectations prompted the negative reaction from investors.
Dentsply Sirona's Q3 earnings missed EPS estimates, causing a sharp stock drop. The company unveiled a new "Return-to-Growth" plan to address performance challenges.
Dental products company Dentsply Sirona (NASDAQ:XRAY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 4.9% year on year to $904 million. The company expects the full year’s revenue to be around $3.65 billion, close to analysts’ estimates. Its non-GAAP profit of $0.37 per share was 17.7% below analysts’ consensus estimates.
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Dentsply Sirona Inc. (NASDAQ: XRAY) breached their fiduciary duties to shareholders.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
In an unprecedented financial spectacle, gold prices have shattered all previous records, surging past an astonishing $4,300 per ounce in mid-October 2025. This historic rally, seeing the precious metal climb nearly 60% year-to-date, marks a profound recalibration of global financial strategies and investor psychology, driven by a powerful confluence
Shares of dental products company Dentsply Sirona (NASDAQ:XRAY)
rose 1.1% in the afternoon session after the U.S. Securities and Exchange Commission (SEC) concluded its investigation into the company's accounting practices and did not intend to recommend any enforcement action. The probe, which began in 2022, had focused on the dental-supplies maker's use of incentives to sell products to distributors in 2021 and whether those incentives were properly accounted for in financial reports. The conclusion of the investigation removed a significant uncertainty for investors. In a filing, Dentsply Sirona noted that it had fully cooperated with the SEC and viewed the closure of the probe without any enforcement action as a "significant and favorable development.".
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
In the last three months, 5 analysts have published ratings on Dentsply Sirona (NASDAQ: XRAY), offering a diverse range of perspectives from bullish to bearish.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
Let’s dig into the relative performance of Dentsply Sirona (NASDAQ:XRAY) and its peers as we unravel the now-completed Q2 dental equipment & technology earnings season.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 16.4%.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
